Glioblastoma multiforme is the most common form of astrocytoma in adults. The incidence of these tumors is highest in the frontal lobes, followed by temporal and parietal lobes, basal ganglia, and occipital lobes. On computed tomography (CT) glioblastoma multiforme typically demonstrates characteristic findings of an irregular enhancing mass, usually surrounded by a significant amount of low-de...

Glioblastoma multiforme is immunogenic and several glioblastoma multiforme-related antigens have now been identified. In addition, the immunologic characteristics of the tumor microenvironment that may affect tumor growth are becoming increasingly understood. The type of immune-based approach selected to treat glioblastoma multiforme will depend on the tumor burden. For minimal disease states, ...

Life expectancy of patients affected by glioblastoma multiforme is extremely low. The therapeutic use of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been proposed to treat this disease based on its ability to kill glioma cell lines in vitro and in vivo. Here, we show that, differently from glioma cell lines, glioblastoma multiforme tumors were resistant to TRAIL stimulat...

Glioblastoma multiforme is the most common primary malignant brain tumor and despite treatment with surgery, radiation, and chemotherapy, the median survival of patients with glioblastoma multiforme is approximately 1 year. Glioblastoma multiforme explants and cell lines have been reported to overexpress the interleukin-13 receptor alpha2 subunit (IL13Ralpha2) relative to nonneoplastic brain. B...

thallium 201 whole body scintigraphy was performed in a 30 year old patient with diffuse osseous metastatic disease secondary to glioblastoma multiforme. multiple sites of thallium uptake correlated with the findings on serial bone scans and radiographs. bone biopsy of a lower lumbar vertebra confirmed that the metastases were of glial origin.

Glioblastoma multiforme is a devastating and intractable type of cancer. Current antineoplastic drugs do not improve the median survival of patients diagnosed with glioblastoma multiforme beyond 14 to 15 months, in part because the blood-brain barrier is generally impermeable to many therapeutic agents. Drugs that target microtubules (MT) have shown remarkable efficacy in a variety of cancers, ...

Glioblastoma multiforme of the cerebellum is rare and comprises a small fraction of all glioblastomas. Eight-five cases have been reported in the literature to date. A 75 year old man is reported with a left cerebellar glioblastoma multiforme. The pathogenesis, course, treatment and prognosis are reviewed.

PURPOSE The chemokine receptor CXCR4 is expressed in many different cancers. In malignant brain tumors, CXCR4 signaling has been implicated in tumor growth, survival, and migration, and pharmacologic inhibition of CXCR4 results in decreased tumor growth in preclinical models. To understand how CXCR4 inhibitors may be incorporated into clinical therapy, we examined determinants of responsiveness...

Posterior fossa glioblastoma multiforme is a very rare childhood tumor with an extremely poor prognosis. There are only few cases of primary cerebellar glioblastoma described in the literature, and primary cerebellar glioblastoma presenting radiologically as a cerebellopontine angle mass lesion has not been reported previously. The authors report a multicentric glioblastoma multiforme in an 11-...

Extracranial metastasis of glioblastoma multiforme (GBM) is very rare, in spite of very aggressive tumor behavior and being documented in only a few patients. In this article we present a 25-year-old man with secondary glioblastoma associated with extracranial progression and distant metastasis. He was diagnosed by magnetic resononce (MR) with an intracranial lesion in the right parietofrontal ...